Hormonal Headaches
It Is Not
Just a Headache.
It Is Hormonal.
Women experience migraines three times more than men — and the mechanism is written in estrogen, CGRP, and the trigeminovascular system. Here is what your brain is actually doing.
I remember the first time I understood that my migraines had a pattern. I had been tracking them for about four months — not scientifically, just in a notes app, writing down dates when the pain arrived with enough force to cancel the day. When I looked at the list, the dates kept clustering around the same point in the month. Not randomly. Predictably. Always the same few days, give or take. Always the days just before my period.
Nobody had told me this was a thing. Not a doctor, not a neurologist, not the two pharmacists I had consulted about whether I was taking too much ibuprofen. I had spent years treating each migraine as an isolated event — a failure of hydration, a response to screen time, a punishment for the glass of wine the night before. I had a list of suspected causes as long as my arm and not one of them said: your estrogen just dropped and your trigeminal nerve is reacting.
Migraine is the fourth leading cause of disability in women globally. Women are three times more likely to have it than men. The sex difference is not present before puberty. It appears with the first menstrual cycle and tracks hormonal fluctuations across the entire reproductive lifespan — intensifying in perimenopause, easing after menopause in many women. The pattern is as hormonal as it could possibly be. And yet most women living with it have never been given a hormonal explanation for what their brain is doing.
This is that explanation.
Migraine Across a Woman's Life
Drag the timeline or click a life stage to see what happens to migraine risk and hormones at each phase
The question of why women get more migraines than men has an increasingly clear molecular answer — even if the full picture is not yet complete. It involves three interacting systems: the trigeminovascular system, the neuropeptide CGRP, and the direct modulatory effect of estrogen on both. Understanding the mechanism does not make the pain less real. But it makes it legible. And legibility is where appropriate treatment starts.
Migraine is not a headache in the ordinary sense. It is a neurological event initiated in the brainstem and hypothalamus, characterised by activation of the trigeminovascular system — a network of trigeminal nerve fibres that innervate the meningeal blood vessels of the brain. When this system activates, it releases a neuropeptide called CGRP (calcitonin gene-related peptide) from the trigeminal afferents. CGRP causes vasodilation in the meningeal vessels, triggers an inflammatory cascade, and drives the throbbing, light-sensitive, nausea-accompanied pain that defines the migraine attack. The drugs that most effectively treat migraine — triptans, and the newer gepants and CGRP monoclonal antibodies — work specifically by blocking this pathway.
Women experience migraine three to four times more than men — and puberty is the inflection point. Population data consistently show that before puberty, migraine prevalence is near-equal between boys and girls. From menarche onward, female prevalence climbs steeply. It peaks at around age 35 — reaching 25–30% of women — then gradually declines, with a steep drop after menopause in many women. The cumulative lifetime prevalence is 43% in women and 18% in men. Migraine is the 4th leading cause of disability in women and the 8th in men [1].
Estrogen directly modulates the trigeminovascular system. Estrogen receptors (ERα, ERβ, and GPER) are highly expressed in CGRP-positive neurons within the trigeminovascular system. Hormonal fluctuations — specifically the fall in estrogen — modulate the excitability of these neurons. In animal models, deficiency of female sex hormones increases CGRP expression in the trigeminal ganglion; estrogen replacement decreases it. A cross-sectional cohort study published in Neurology found that women with episodic migraine showed significantly higher CGRP concentrations during menstruation — the low-estrogen window — than during the periovulatory period when estrogen peaks [2].
The estrogen withdrawal hypothesis — and its nuance. The dominant mechanistic explanation for menstrual migraine is estrogen withdrawal: the premenstrual drop in estrogen removes a modulatory brake on the trigeminovascular system, lowering the threshold for CGRP release and migraine initiation. A critical review published in the Journal of Headache and Pain assessed the body of evidence for this hypothesis and found it widely accepted but methodologically heterogeneous — most studies are small, with variable case definitions. The authors call for larger, better-standardised research. What is clear is that estrogen withdrawal is a significant contributor, and that a second mechanism — prostaglandin release at menstruation — acts in parallel, further sensitising trigeminal afferents [3].
The lifecycle pattern confirms hormonal causation. A comprehensive review of migraine across reproductive events found that migraine onset increases sharply at menarche (10–20% of women report their first migraine at the start of their periods), often improves during the high-stable-estrogen environment of the second and third trimesters of pregnancy, worsens postpartum as estrogen crashes, and fluctuates significantly in perimenopause as estrogen becomes erratic before its final decline. Each of these changes tracks estrogen dynamics precisely — a pattern that would be inexplicable if hormones were not the primary driver [4].
Hypothalamic hormones compound the picture. A 2026 review in the Journal of Headache and Pain established that the hypothalamus — a key migraine generator — is directly linked to sex hormone signalling. A fall in plasma estrogen, progesterone, and hypothalamic oxytocin may trigger migraine attacks, while higher levels appear protective. The trigeminovascular system carries receptors for all three. This means migraine susceptibility in women is not just about ovarian hormones — it involves the entire neuroendocrine axis, with the hypothalamus integrating hormonal signals and feeding them directly into the migraine circuit [5].
Estrogen receptors are expressed directly on the CGRP-positive neurons that initiate migraine attacks. When estrogen drops, those neurons become more excitable. The migraine is not random. It is a withdrawal response.
Inside the Migraine Brain
Click any brain region or mechanism below to understand what it does in a hormonal migraine
The clinical implications of hormonal migraine are significant and still insufficiently implemented in most medical encounters. The first is diagnostic: a woman who reports migraines clustering around menstruation — in the window of days −2 to +3 from the start of flow — meets the criteria for menstrual migraine (menstrually related or pure menstrual), a recognised clinical entity with specific treatment implications. Most women with this pattern have never been told it has a name.
The second implication is pharmacological. Menstrual migraines tend to be longer, more severe, and less responsive to standard triptans than non-menstrual attacks — partly because they occur in a different hormonal and inflammatory environment, and partly because prostaglandins are a co-trigger alongside estrogen withdrawal. Short-term prophylaxis — using a frovatriptan, naproxen, or continuous low-dose estrogen supplementation in the perimenstrual window — is an evidence-based option that most women are never offered because no one has framed their migraine as hormonal.
The third is about menopause. Perimenopause — the transition phase — is often the worst period for migraine because estrogen becomes erratic: high one week, crashing the next, never stable. It is the fluctuation itself, not just the level, that sensitises the trigeminovascular system. After menopause, when estrogen settles at a new stable low, many women find their migraines improve significantly. This is not magic. It is the stabilisation of the very hormone whose fluctuations had been triggering attacks for decades.
Your Migraine Risk Window
Select your cycle day and current triggers to see your personalised hormonal risk context
The most important thing you can do with a hormonal migraine pattern is document it, name it, and bring it to a healthcare provider with the specific language that unlocks the appropriate treatment. Here is what that looks like in practice.
The diagnostic criteria for menstrual migraine require attacks occurring on day 1 ±2 of menstruation in at least 2 of 3 consecutive cycles. Three months of tracking with specific cycle day notation is both sufficient and necessary for diagnosis. A simple headache diary — noting intensity, duration, and cycle day — gives your clinician everything needed to make the determination.
Walk in with the phrase "menstrually related migraine" or "pure menstrual migraine." These are recognised ICHD-3 diagnostic classifications with specific treatment pathways. Without this framing, migraine is likely to be treated generically. With it, short-term perimenstrual prophylaxis — frovatriptan, naproxen sodium, or transdermal estrogen — becomes a discussable option. The language you use determines the treatment you are offered.
The estrogen withdrawal trigger is not controllable without medical intervention. But the co-triggers that amplify it — sleep disruption, skipped meals, dehydration, alcohol, high stress — all interact with an already sensitised trigeminovascular system. In the perimenstrual window, the threshold for attack initiation is lower. Protecting sleep, maintaining blood sugar stability with protein-anchored meals, hydrating adequately, and avoiding alcohol in days −3 to +2 of your cycle are the highest-leverage behavioural interventions available without a prescription.
The development of CGRP-targeting therapies — gepants (ubrogepant, rimegepant) and monoclonal antibodies (erenumab, fremanezumab, galcanezumab) — represents the most significant advance in migraine treatment in a generation. These drugs work precisely at the molecular pathway that estrogen withdrawal sensitises. Several are now approved for both acute treatment and prevention of chronic migraine. They do not interact with hormonal contraception. Women with hormonally driven migraine with aura, who carry specific contraindications to estrogen-containing contraceptives, now have effective alternatives that their GP may not have offered because the field is moving faster than general practice awareness.
I think about the years of treating migraine as something random happening to me rather than something predictable happening in me. The blame I assigned to wine, to screens, to stress — none of which were wrong, exactly, but none of which were the primary variable. The primary variable was the date. And the date was telling me something specific about my estrogen, my CGRP, and my trigeminovascular system's threshold in that particular window of the month.
The pattern was always there. I just did not have the language for it — and neither, it turns out, did most of the healthcare providers I had seen. Migraine is the most common disabling neurological disorder in women. It affects 43% of us across our lifetimes. It clusters around our reproductive hormones with the regularity of a tide. And the majority of women living with it have been told it is "just a headache" and offered ibuprofen.
It is not just a headache. It is a neurological event with a hormonal trigger, a specific molecular cascade, a recognised diagnostic classification, and an expanding menu of targeted treatments. You deserve all of that information. You have always deserved it.
Track the pattern. Name it. Bring the science. ❤References
- Vetvik, K. G., & MacGregor, E. A. (2017). Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. The Lancet Neurology, 16(1), 76–87. https://doi.org/10.1016/S1474-4422(16)30293-9
- Raffaelli, B., et al. (2023). Sex hormones and calcitonin gene-related peptide in women with migraine: A cross-sectional, matched cohort study. Neurology, 100(10), e1044–e1053. https://doi.org/10.1212/WNL.0000000000207114
- Raffaelli, B., Do, T. P., Chaudhry, B. A., Ashina, M., Amin, F. M., & Ashina, H. (2023). Menstrual migraine is caused by estrogen withdrawal: Revisiting the evidence. Journal of Headache and Pain, 24, 131. https://doi.org/10.1186/s10194-023-01664-4
- Na, M. K., et al. (2024). Migraines in women: A focus on reproductive events and hormonal milestones. Headache and Pain Research, 25(1), 3–15. https://doi.org/10.62087/hpr.2024.0003
- Warfvinge, K., Edvinsson, J. C. A., Maddahi, A., & Edvinsson, L. (2026). Hypothalamic and sex-related hormones in migraine. Journal of Headache and Pain, 27. https://doi.org/10.1186/s10194-026-02289-z